Save up to 40 percent on stays through December 31, 2013

MCLEAN, VA. - Monday, November 19th 2012 [ME NewsWire]

(BUSINESS WIRE)-- Hilton HHonors, the loyalty program for Hilton Worldwide's 10 distinct hotel brands, has launched its Any Weekend, Anywhere Sale, giving travelers added incentive to make the most of their weekends. Beginning today, guests can save up to 40 percent on weekend stays completed through December 31, 2013 at participating hotels and resorts in the Hilton HHonors portfolio, including Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Hilton Hotels & Resorts, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations.

To take advantage of the Any Weekend, Anywhere Sale, guests can reserve and complete stays as follows:

    Europe, Middle East and Africa:Book from November 19, 2012 to January 31, 2013, for ... Read more »

GOTHENBURG, Sweden - Monday, November 19th 2012 [ME NewsWire]

(BUSINESS WIRE)--According to fresh market data from UK analysts MZA Ltd, Ascom Wireless has grown its market shares and is now sharing the position as the world’s largest manufacturer of professional cordless phones together with Gigaset.

Ascom Wireless also reports a successfully completed on-site inspection by the Swedish Medical Products Agency, concluding that the company complies with the EU Medical Device Directive.

Ascom Wireless Solutions is increasing its share of the total global market for professional PBX connected cordless phones. According to market data from UK analysts MZA Ltd, Ascom Wireless’ share of the market is now 17 percent, on par with the historic leader Gigaset, whose global market share dropped by 1 percent during the same period.

In the first half of 2012, Ascom Wireless sold 186,000 professional cordless phones, up from 171,000 for the corresponding period in 2011. Th ... Read more »

PORTLAND, Ore. - Saturday, November 17th 2012 [ME NewsWire]

(BUSINESS WIRE)-- CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has entered into a clinical trial agreement with Jeffrey Jacobson, M.D., professor and chief of the Division of Infectious Diseases and HIV Medicine at Drexel University College of Medicine, to conduct additional Phase II studies with PRO 140, an experimental humanized monoclonal antibody (mAb) targeting the CCR5 receptor for the treatment of HIV infection.

This agreement establishes a formal collaboration between Drexel University College of Medicine and CytoDyn to allow Drexel to proceed with two NIH-funded Phase IIB clinical trials totaling approximately 10 million dollars awarded to Dr. Jacobson for the study of PRO 140. The first study, entitled "Long-Acting HIV Therapy for Injection Drug Users ("NIDA Stu ... Read more »